⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IRWD News
Ironwood Pharmaceuticals, Inc. - Class A
Form 8-K
sec.gov
IRWD
Form 8-K/A
sec.gov
IRWD
Form 8-K
sec.gov
IRWD
Form 8-K
sec.gov
IRWD
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
businesswire.com
IRWD
Convergent Therapeutics Names Andrew Davis Chief Business and Strategy Officer
businesswire.com
DVAX
IRWD
MRK
BHC
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week ® 2026
businesswire.com
IRWD
Form 8-K
sec.gov
IRWD
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
businesswire.com
IRWD
Form 8-K
sec.gov
IRWD